# Referenties bij MAGMA 4-2013

## FARMACOTHERAPIE – Ontijzering, p. 125–127

1. Van Bokhoven MA, Van Deursen CThBM, Swinkels DW. Diagnosis and management of hereditary haemochromatosis. *BMJ 2011*;342:218–223.
2. EASL clinical practice guidelines for HFE hemochromatosis.
*J Hepatoll 2010*;53(1):3–22.
3. Brissot P, Ball S, Rofail D, Cannon H, Jin VW. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion 2011;51(6):1331–8.
4. Rombout-Sestrienkova E, Nieman FHM, Essers BAB, Van Noord PAH, Janssen MCH, Van Deursen CThBM, Bos, LP, Rombout F, Van den Braak R, De Leeuw PW, Koek GH: Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
*Transfusion 2012*;52:470–477.
5. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice- Evidence- Based Approach from the Writing Committee of the American Society for Apheresis.
*Journal of Clinical Apheresis 2013*;28:145–284
6. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
*Gut 2007*;56:1291–5.

## FARMACOTHERAPIE – Generieke protonpompremmers: zijn ze uitwisselbaar?

## p. 127–129

1. www.cbg-meb.nl, SmPCs van PPIs, geraadpleegd op 18 oktober 2013.
2. Otten MH, Lekkerkerker JFF, Mulder CJJ. Waarom sommige protonpompremmers meer gelijk zijn dan andere. *Ned Tijdschr Geneeskd. 2009*;153:B414
3. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, VAN Schaik RH, Kuipers EJ, Kooiman JC, Geus WP. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. *Aliment Pharmacol Ther. 2010*; Jan;31(1):150–9.
4. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. *Aliment Pharmacol Ther. 2012*; Apr;35(7):810–8.
5. Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Tazuma S. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole. *Dig Liver Dis. 2006*; Aug;38(8):554–9.
6. Shimatani T, Hirokawa S, Tawara Y, Hamai K, Matsumoto M, Tazuma S, Inoue M. Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence. *Dig Dis Sci. 2009*; Nov;54(11):2385–90.
7. Tahmassian et al. De patiënt had toch gelijk. *Pharmaceutisch Weekblad 2005*;26:877.

## LEVER – Primaire scleroserende cholangitis: Epidemiologie en ziekteverloop, p. 130 –131

1. Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. *Semin Liver Dis 1997*;17:13–22.
2. Kirsten Boonstra, Rinse K. Weersma, Karel J. van Erpecum, Erik A. Rauws, B.W. Marcel Spanier, Alexander C. Poen, Karin M. van Nieuwkerk, Joost P. Drenth, Ben J. Witteman, Hans A. Tuynman, Anton H. Naber, Paul J. Kingma, Henk R. van Buuren, Bart van Hoek, Frank P. Vleggaar, Nan van Geloven, Ulrich Beuers, and Cyriel Y. Ponsioen, on behalf of the EpiPSCPBC StudyGroup. Population-Based Epidemiology, Malignancy Risk and Outcome of Primary Sclerosing Cholangitis. *Hepatology 2013*; Jun 14. doi: 10.1002/hep.26565

## LEVER – Nationaal MDL-geïnitieerd programma voor substantiële gezondheidswinst, p. 132–133

1. <http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=7052_95&D1=5&D2=0&D3=0&D4=46-62&VW=T>
2. <http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=7052_95&D1=44&D2=0&D3=0&D4=18-60&HDR=G1,G2,G3&STB=T&VW=T>
3. <http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=80202NED&D1=4-5,14,60&D2=0&D3=a&D4=0-4,61,63,76,78&D5=a&VW=T>
4. Ward JW, Lok ASF, Thomas DL, et al.. Chronic Viral Hepatitis–Strategies to Improve Effectiveness of Screening and Treatment. *Hepatology 2012*;55:307–315.
5. Zuure FR, Bouman J, Vanhommerig JW, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. *Liver International 2013*; 33:727–738.
6. Hahné SJ, Melker de HE, Kretzschmar M, et al. Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007. *Epidemiol Infect 2012*; 140:1469–1480.
7. Vriend HJ, van Veen MG, Prins M et al. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. *Epidemiol Infect 2012* doi:10.1017/S0950268812001884.
8. Veldhuijzen IK, Wolter R, Rijckborst V, et al. Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, The Netherlands. *J Hepatol 2012*; 57: 1171–1176.
9. Logtenberg-van der Grient H , Boland G, Mostert M, Schalm SW. Onnodige sterfte door hepatitis B en C. *Medisch Contact 2012*; 67: 456–9.

## CASUÏSTIEK – Enteropathie-geassocieerd T-cellymfoom p. 143

1. d'Amore F, Relander T, Lauritzsen GF et al. Up-front autologous stem-cell transplantation in peripheral T‑cell lymphoma: NLG‑T‑01. *J Clin Oncol 2012*; 30:3093–3099.
2. Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T‑cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. *Blood 2010*; 115:3664–3670.